PBRM1 and nonpapillary renal cell carcinoma: Recent studies have suggested that in ccRCC, PBRM1 mutations are associated with better responses to anti-PD1 therapy.43,44 The increased lymphocyte infiltration and higher PD-1 expression in the CD3high subgroup of our cohort fits well with these observations.